Prime Medicine, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Prime Medicine, Inc. - overview
Established
2019
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Prime Medicine, Inc. , based in the US, focuses on advancing gene editing solutions through its innovative Prime Editing technology aimed at curing genetic disorders. Founded in 2019 and headquartered in Cambridge, US, Prime Medicine, Inc. specializes in gene editing with a focus on Prime Editing technology.
The company has completed 7 total deals, with its most recent funding round occurring on February 14, 2024, when it raised USD 24. 00 mn from the Cystic Fibrosis Foundation, bringing the total amount raised to USD 24. 00 mn. Prime Medicine specializes in the development of Prime Editing technology, a next-generation gene editing platform that provides precise modifications to the genome.
This technology aims to address the genetic causes of various diseases, enabling long-lasting cures for patients by targeting approximately 90% of known disease-causing mutations. The company serves biotechnology firms, research institutions, and healthcare providers, focusing on North America, Europe, and Asia. For the most recent year, Prime Medicine reported revenue of USD 4. 63 mn and an EBITDA of USD -199.
09 mn. Revenue is generated through strategic partnerships, B2B agreements, and licensing arrangements related to the Prime Editing technology, with a focus on facilitating advancements in gene editing therapies. Looking ahead, Prime Medicine plans to launch new products leveraging its Prime Editing technology and expand into new geographical markets, including Europe and Asia, by 2025. The recent funding of USD 24.
00 mn will support the development of these new initiatives, enhancing their capacity to deliver innovative solutions in the biotechnology sector.
Current Investors
ARCH Venture Partners, F-Prime Capital, GV
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.primemedicine.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Prime Medicine, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Prime Medicine, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.